The Company is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology. The Company was established on November 16, 2006. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on September 20, 2019.
Headquarters
20th Floor, 16-4, Dongbaekjungang-ro 16beon-gil Giheung-gu Yongin-si Gyeonggi
Yongin; Gyeonggi;
Contact Details: Purchase the Olipass Corporation report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service